1. Home
  2. LIF vs EWTX Comparison

LIF vs EWTX Comparison

Compare LIF & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Life360 Inc.

LIF

Life360 Inc.

HOLD

Current Price

$55.61

Market Cap

3.7B

Sector

N/A

ML Signal

HOLD

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

HOLD

Current Price

$40.51

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LIF
EWTX
Founded
2008
2017
Country
United States
United States
Employees
547
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.7B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LIF
EWTX
Price
$55.61
$40.51
Analyst Decision
Strong Buy
Buy
Analyst Count
11
6
Target Price
$75.58
$39.00
AVG Volume (30 Days)
725.3K
1.6M
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$36.21
N/A
Revenue Next Year
$20.80
N/A
P/E Ratio
$425.29
N/A
Revenue Growth
N/A
N/A
52 Week Low
$37.01
$12.31
52 Week High
$112.54
$48.40

Technical Indicators

Market Signals
Indicator
LIF
EWTX
Relative Strength Index (RSI) 60.19 51.88
Support Level $51.68 $29.03
Resistance Level $59.45 $43.93
Average True Range (ATR) 3.01 2.68
MACD -0.33 -0.26
Stochastic Oscillator 65.97 22.26

Price Performance

Historical Comparison
LIF
EWTX

About LIF Life360 Inc.

Life360 is the world's largest family focused social network, with nearly 100 million monthly active users. Security-conscious families use the Life360 app to track each other's whereabouts and to track the location of their pets and personal belongings. Life360 also offers a suite of additional security features, such as driver safety monitoring, roadside assistance, and emergency dispatching. In the US, the Life360 app regularly ranks in the top 10 most popular social-networking apps and in the top 25 across all apps in terms of daily active users.

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.

Share on Social Networks: